Postoperative pain management refers to the treatment of moderate-to-severe pain following surgical procedures, aiming to enhance recovery and patient comfort. The prevalence of such pain exhibits geographic variability, with rates ranging from 14% to 55% in Western countries. According to the postoperative pain management pipeline analysis by Expert Market Research, the pipeline landscape is witnessing steady growth due to rising surgical volumes and increasing demand for safer, more effective therapeutics. The pipeline includes innovative non-opioid drugs, nerve block agents, and multimodal analgesic strategies, reflecting a strong focus on personalized and targeted therapies.
Major companies involved in the postoperative pain management pipeline analysis include Avenue Therapeutics, Inc., Jiangsu HengRui Medicine Co., Ltd., and others.
Leading drugs currently in the pipeline include TLC590, Tramadol, and others.
Increased clinical trials on long-acting regional anesthetics, adoption of multimodal pain control strategies, and innovation in extended-release formulations are driving pipeline expansion in postoperative care.
The Postoperative Pain Management Pipeline Analysis Report by Expert Market Research gives comprehensive insights into postoperative pain management therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for postoperative pain management. The postoperative pain management report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The postoperative pain management pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with postoperative pain management treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to postoperative pain management.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Postoperative pain management refers to the clinical practices used to control pain that arises after a surgical procedure. It occurs due to tissue damage, inflammation, or nerve irritation following surgery, often resulting in moderate to severe acute pain. Effective management is essential to promote healing, prevent complications, and improve patient comfort and recovery outcomes.
Postoperative pain is treated using a range of methods, including analgesics (opioid and non-opioid), regional anesthesia, and multimodal approaches to minimize pain while reducing side effects and opioid dependency. In January 2025, Vertex Pharmaceuticals Incorporated received FDA approval for Journavx (suzetrigine), a first-in-class oral non-opioid drug, marking a major advancement in the postoperative pain management pipeline.
A 2024 study highlights a significant incidence of moderate to severe postoperative pain, with 41%-61% in developed countries and 60%-80% in developing nations. The American Pain Society reports a persistent prevalence exceeding 80%. In India alone, approximately 30 million surgical procedures are performed annually. These statistics underscore the urgent need for effective postoperative pain management, driving innovation and expansion in the drug development pipeline globally.
This section of the report covers the analysis of postoperative pain management drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase IV holds 50.58% of the postoperative pain management clinical trials, showcasing a strong presence of approved therapies with real-world effectiveness, driving confidence in market growth. Phase III accounts for 21.01%, indicating a healthy advancement of late-stage candidates. Phase II represents 15.95%, followed by phase I at 7.39% and early phase I at 5.06%, reflecting a promising and continuous innovation cycle in postoperative pain management.
The drug molecule categories covered under the postoperative pain management pipeline analysis include small molecules, biologics, natural products, local anesthetics, gene therapies, and others. The postoperative pain management report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for postoperative pain management.
Opioid-based analgesics remain central in postoperative pain management for paediatric patients. For example, the POPCORN trial is evaluating the comparative side-effect profiles of intravenous morphine and oxycodone used in patient-controlled analgesia. This Phase 4 trial aims to assess differences in antiemetic use, opioid efficacy, and adverse effects, enhancing evidence-based opioid selection in clinical practice.
The EMR report for the postoperative pain management pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed postoperative pain management therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in postoperative pain management clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for postoperative pain management. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of postoperative pain management drug candidates.
TLC590, sponsored by Taiwan Liposome Company, is currently undergoing a Phase II/III trial to evaluate its safety, pharmacokinetics, and efficacy in postsurgical pain management after inguinal hernia repair. This liposomal formulation of ropivacaine aims to provide extended local pain relief. The study is assessing two doses of TLC590 through a double-blind, comparator- and placebo-controlled design.
IV Tramadol is being evaluated by Avenue Therapeutics, Inc. in a Phase III study comparing its efficacy and safety to placebo and morphine for managing post-operative pain after abdominoplasty. The study is examining IV tramadol’s dual mechanism—opioid receptor agonism and monoaminergic reuptake inhibition—as a novel approach to deliver effective analgesia with a potentially lower risk of abuse.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Postoperative Pain Management Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for postoperative pain management. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into postoperative pain management collaborations, regulatory environments, and potential growth opportunities.
Global Pain Management Devices Market Report and Forecast
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share